Transmucosal drug delivery device and method including microneedles

• US 9,017,310 B2
• Filed: 10/08/2009
• Issued: 04/28/2015
• Est. Priority Date: 10/08/2009
• Status: Active Grant

• Current Assignee: Xerox Corporation (Xerox Holdings Corp.)
• Original Assignee: Palo Alto Research Center, Inc. (Xerox Holdings Corp.)
• Inventors: Uhland, Scott, Peeters, Eric
• Primary Examiner(s): Berdichevsky, Aarti B
• Assistant Examiner(s): SCHELL, LAURA C
• Application Number:
  US12/576,075
• Publication Number:
  US 20110087195A1
• Time in Patent Office: 2,028 Days
• Field of Search: 604/890.1, 604/891.1, 604 20- 22, 604/264, 604/272, 604/239, 604/506, 604/48, 604/514, 604/515, 604/93.01, 604/285
• US Class Current: 604/890.1
• CPC Class Codes: A61M 2037/0023 Drug applicators using microneedles
• CPC Class Codes: A61M 31/002 Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50
• CPC Class Codes: A61M 37/0015 by using microneedles

Abstract

Devices and methods for transmucosal drug delivery are provided. A device includes a housing configured for intralumenal deployment into a human or animal subject; a drug-dispensing portion which contains at least one drug; and a plurality of microneedles extending, or being extendable from, the housing, the plurality of microneedles being configured to disrupt at least one region of a mucosal barrier adjacent the housing at a selected time after being intralumenally deployed in the human or animal subject. The device is operable to dispense the drug from the housing to a region of the mucosal barrier disrupted by the plurality of microneedles.

Claims

1. An intravaginal device for transmucosal drug delivery comprising:

a housing shaped and dimensioned for intravaginal deployment and for holding the device in place in the vagina by frictional engagement between the housing and mucosal tissue of a human or animal subject;

a drug-dispensing portion which contains at least one drug disposed in the housing;

a plurality of solid microneedles extending, or being extendable from, the housing, the plurality of microneedles being configured to disrupt at least one region of a mucosal barrier adjacent the housing at a selected time after being intralumenally deployed in the human or animal subject; and

a control module comprising a power source and a controller, the controller being configured to actuate release of the at least one drug from the housing after the plurality of solid microneedles penetrate the mucosal barrier,

wherein the device is operable to dispense the drug from the housing to a region of the mucosal barrier disrupted by the plurality of solid microneedles.

2. The device of claim 1, wherein the drug comprises a protein or peptide.

3. The device of claim 1, wherein the drug comprises a hormone or steroid.

4. The device of claim 1, further comprising a receiver adapted to receive power or control signals from a transmitting device when the device is intralumenally deployed in the human or animal subject.

5. The device of claim 1, wherein the drug dispensing portion comprises a positive displacement element for actively dispensing the drug from the housing, the positive displacement element being selected from the group consisting of a mechanical displacement element, an osmotic swelling displacement element, a gas-volume displacement element, a magnetically-induced phase transformation element, a thermally-induced phase transformation element, a piezoelectric actuator, an electrostatically-induced compression element, an actuatable dispensing valve with a static pressure head, and a combination thereof.

6. The device of claim 1, further comprising an actuator configured to move the plurality of solid microneedles from a first position to a second position in which the plurality of solid microneedles penetrate the mucosal barrier at the selected time.

7. The device of claim 6, wherein the solid microneedles are contained within the housing in the first position.

8. The device of claim 6, wherein a controller is configured to actuate the release of the at least one drug after the plurality of solid microneedles are actuated to the second position.

9. The device of claim 1, further comprising a dissolvable coating or a moveable covering configured to expose the solid microneedles at the selected time after deployment of the device.

10. The device of claim 9, wherein a controller is configured to actuate the release of the at least one drug after the plurality of solid microneedles are exposed.

11. A method for local transmucosal delivery of a drug to a human or animal subject comprising:

deploying a drug delivery device within a vagina of a human or animal subject, the drug delivery device comprising a housing shaped and dimensioned for intravaginal deployment and for holding the device in place in the vagina by frictional engagement between the housing and mucosal tissue, and a drug-dispensing portion contained within the housing;

penetrating the mucosal tissue with a plurality of solid microneedles that extend from, or are extendable from, the housing at a selected time after the drug delivery device is deployed in the lumen; and

dispensing a drug from the drug-dispensing portion through one or more openings in the housing to the region of the mucosal tissue that is disrupted by the microneedles.

12. The method of claim 11, wherein the drug comprises a protein or peptide.

13. The method of claim 11, wherein the drug is dispensed from the drug delivery device via a positive displacement process.

14. The method of claim 13, wherein the positive displacement process comprises mechanical displacement, osmotic swelling displacement, gas-volume displacement, magnetically-induced phase transformation, thermally-induced phase transformation, piezoelectric actuation, electrostatically-induced compression, static pressure head displacement through an actuatable dispensing valve, or a combination thereof.

15. The method of claim 11, wherein penetrating the mucosal tissue comprises moving a plurality of solid microneedles from a first position to a second position in which the plurality of solid microneedles penetrate the mucosal barrier.

16. The method of claim 11, wherein penetrating the mucosal tissue comprises dissolving a dissolvable coating or moving a moveable covering to expose the solid microneedles at the selected time after deployment of the device.

17. The method of claim 11, wherein after penetrating the mucosal tissue, the microneedles are withdrawn into the housing before the drug is dispensed from the housing.

18. An intravaginal device for transmucosal drug delivery comprising:

a cylindrical housing shaped and dimensioned for intravaginal deployment and for holding the device in place in the vagina by frictional engagement between the housing and mucosal tissue of a human or animal subject, the housing having an elongated sidewall disposed between opposed ends;

a plurality of microneedles extending from, or extendable from, the elongated sidewall of the housing, the microneedles being configured to penetrate a region of the mucosal barrier adjacent to the sidewall of the housing at a selected time after the device is intravaginally deployed in the human or animal subject, and

a drug dispenser comprising a drug repository containing at least one drug and a positive displacement element adapted to dispense the at least one drug from the elongated sidewall of the housing through the plurality of microneedles or onto the region of the mucosal tissue disrupted by the microneedles.

19. The device of claim 18, further comprising a controller configured to control the actuation of the positive displacement element.

20. The device of claim 18, wherein the positive displacement element is selected from the group consisting of a mechanical displacement element, an osmotic swelling displacement element, a gas-volume displacement element, a magnetically-induced phase transformation element, a thermally-induced phase transformation element, and a combination thereof.

21. The device of claim 18, wherein the drug comprises a protein or peptide.

22. The device of claim 18, further comprising an actuator configured to move the plurality of microneedles from a first position to a second position in which the plurality of microneedles penetrate the mucosal barrier at the selected time.

23. The device of claim 18, further comprising a dissolvable coating or a moveable covering configured to expose the microneedles at the selected time after deployment of the device.

24. The device of claim 18, wherein the sidewall comprises a plurality of openings configured to dispense the drug therethrough in at least two opposed directions from the sidewall.

25. The device of claim 18, wherein the microneedles are solid.